• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Pharmacophore modeling, 3D-QSAR studies and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors

tetano

Editor, Senior Moderator
Chem Biol Drug Des. 2011 Dec 16. doi: 10.1111/j.1747-0285.2011.01299.x. [Epub ahead of print]
Pharmacophore modeling, 3D-QSAR studies and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors.
Zhang J, Pan X, Wang C, Wang F, Li P, Xu W, He L.
Source

College of Medicine, Xi'an Jiaotong University, No. 76, Yanta West Road, Xi'an, Shaanxi Province, 710061, P.R. China Department of Medicinal Chemistry, School of Pharmacy, Shandong University, Ji'nan, Shandong 250012, P. R. China.
Abstract

Neuraminidase (NA) is a major glycoprotein of influenza virus which is essential for viral infection. It offers a potential target for antiviral drug development. In order to develop potent NA inhibitors, pharmacophore models were generated by GALAHAD. 3D-QSAR studies were carried out on 49 molecules. Both CoMFA (q(2) = 0.720 and r(2) = 0.947) and CoMSIA (q(2) = 0.644 and r(2) = 0.885) yielded reasonable results. A preliminary pharmacokinetic profile of these NAIs was predicted using Volsurf module. ? 2011 John Wiley & Sons A/S.

? 2011 John Wiley & Sons A/S.

PMID:
22222003
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22222003
 
Back
Top Bottom